½ÃÀ庸°í¼­
»óǰÄÚµå
1457362

¼¼°èÀÇ ·¡Æ® ¸ðµ¨ ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«) : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)

Rat Model Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 211 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Persistence Market Research´Â ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀå¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» ¹ßÇ¥Çϰí ÁÖ¿ä ½ÃÀå ¿ªÇÐ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦ ¹× ½ÅÈï µ¿Çâ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ °³¿ä¸¦ Á¦°øÇß½À´Ï´Ù. ÀÌ º¸°í¼­´Â ·¡Æ® ¸ðµ¨ ½ÃÀåÀÇ ±¸Á¶¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®À» Á¦°øÇϰí 2023³âºÎÅÍ 2030³â±îÁö ½ÃÀå ¼ºÀå ±Ëµµ¸¦ ¿¹ÃøÇÏ´Â µ¶Á¡ µ¥ÀÌÅÍ¿Í Åë°è¸¦ Á¦½ÃÇÕ´Ï´Ù.

¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀåÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.8%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç 2023³â 13¾ï ´Þ·¯¿¡¼­ 2030³â 21¾ï ´Þ·¯ÀÇ Æò°¡¾×¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

  • ·¡Æ® ¸ðµ¨ ½ÃÀå ±Ô¸ð(2023³â) : 13¾ï ´Þ·¯
  • ¿¹Ãø ½ÃÀå °¡Ä¡(2030³â) : 21¾ï ´Þ·¯
  • ½ÃÀå ¼ºÀå·ü(º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 2023³â-2030³â) : 6.8%
  • °ú°Å ½ÃÀå ¼ºÀå·ü(º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 2018³â-2022³â) : 7.5%

·¡Æ® ¸ðµ¨ ½ÃÀå : Á¶»ç ¹üÀ§

½ÇÇè¿ë Áã·Îµµ ¾Ë·ÁÁø ·¡Æ® ¸ðµ¨Àº Àΰ£°ú »ý¹°ÇÐÀûÀ¸·Î À¯»çÇϱ⠶§¹®¿¡ »ý¸®ÇÐ, À¯ÀüÇÐ, ÇൿÇÐ, Áúº´ ¿¬±¸ µî ´Ù¾çÇÑ ºÐ¾ßÀÇ °úÇÐÀû Á¶»ç¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¹ø½ÄÁֱⰡ ª°í ´Ù·ç±â ½±±â ¶§¹®¿¡ ÀÌ·¯ÇÑ ¸ðµ¨Àº ÀǾàǰ °³¹ß, µ¶¼º ÇÐÀû ºÐ¼® ¹× º¹ÀâÇÑ »ý¹°ÇÐÀû ¸ÞÄ¿´ÏÁòÀÇ ÇØ¸í¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¸¸¼º Áúȯ Áõ°¡¿Í À¯Àü °øÇÐÀÇ Áøº¸¿¡ ÈûÀÔ¾î ÀǾàǰ °³¹ß¿¡ À־ÀÇ ÀüÀÓ»ó½ÃÇè ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ´Â °ÍÀÌ, ·§Æ® ¸ðµ¨ »ê¾÷ÀÇ ´ëÆøÀûÀÎ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Àΰ£ÀÇ ´Ù¾çÇÑ »óŸ¦ ¸ð¹æÇÏ´Â ´É·ÂÀÌ ¿¬±¸ÀÇ À¯¿ë¼ºÀ» ³ôÀÌ°í ·¡Æ® ¸ðµ¨ ½ÃÀå ÀüüÀÇ È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:

À¯ÀüÀÚ °øÇÐÀÇ Áøº¸, ƯÈ÷ CRISPR-Cas9 ±â¼úÀº Á¤È®ÇÑ À¯ÀüÀÚ ÆíÁýÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ·¡Æ® ¸ðµ¨ ½ÃÀå¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ÀüÀÓ»ó½ÃÇèÀÇ Å¸´ç¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ ±â¼ú Çõ½ÅÀº Ç¥Àû µ¹¿¬º¯ÀÌ¿Í À¯ÀüÀÚ ³ì¾Æ¿ôÀÌ °¡´ÉÇÏ°Ô µÇ¾î ¾ÏÀ̳ª ½Å°æ Áúȯ µî ·¡Æ® ¸ðµ¨À» ÀÌ¿ëÇÏ¿© ¿¬±¸ÇÒ ¼ö ÀÖ´Â ÁúȯÀÇ ¹üÀ§°¡ È®´ëµÇ¾ú½À´Ï´Ù. µ¿½Ã¿¡ ´ç´¢º´°ú ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ ¼¼°è È®»êÀÌ È®´ëµÊ¿¡ µû¶ó ±Ùº»ÀûÀÎ ºÐÀÚ °æ·Î¸¦ ã±â À§ÇØ Áã¿Í °°Àº ½Å·ÚÇÒ ¼öÀÖ´Â µ¿¹° ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ·¡Æ® ¸ðµ¨Àº »ý¸®Àû, À¯ÀüÇÐÀûÀ¸·Î Àΰ£°ú À¯»çÇϱ⠶§¹®¿¡ ÀǾàǰ °³¹ß °úÁ¤¿¡¼­ ÇʼöÀûÀÌ¸ç ½ÃÀå ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ:

Áã¿Í Àΰ£ »çÀÌ¿¡ °íÀ¯ÇÑ »ý¸®ÇÐÀû Â÷À̰¡ Àֱ⠶§¹®¿¡ ·¡Æ® ¸ðµ¨ »ê¾÷¿¡ À־, Áã ¿¬±¸¿¡¼­ ¾òÀº Áö°ßÀ» Àΰ£ÀÇ ÀÓ»ó °á°ú¿¡ ¹Ý¿µÇÏ´Â °ÍÀº ÇöÀúÇÑ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ÇѰè´Â ÀüÀÓ»ó ¿¬±¸ÀÇ Æ®·£½º·¹À̼ųΠ°ü·Ã¼ºÀ» ¹æÇØÇϰí, ÁãÀÇ µ¥ÀÌÅ͸¸À» ±â¹ÝÀ¸·Î ÇÏ´Â Àΰ£¿¡¼­ÀÇ Ä¡·á ¾ÈÀü¼º ¹× È¿´ÉÀÇ ¿¹ÃøÀ» º¹ÀâÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ µ¿¹° ¿¬±¸, ƯÈ÷ Áã¿¡ ´ëÇÑ À±¸®Àû ¹× ±ÔÁ¦ ¿ì·Á°¡ ½É°¢ÇÑ Àå¾Ö¹°À̵Ǿú½À´Ï´Ù. º¸´Ù ¾ö°ÝÇÑ ¹ýÀû Ʋ°ú Ä¿Áö´Â »çȸÀû ¿ì·Á ¼Ó¿¡¼­ °úÇÐÀû Áøº¸¿Í À±¸®Àû °í·Á»çÇ×ÀÇ ±ÕÇüÀ» ¸ÂÃß´Â °ÍÀº ·¡Æ® ¸ðµ¨ ½ÃÀåÀ» Ž»öÇϴµ¥ À־ º¹À⼺À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ:

·¡Æ® ¸ðµ¨ »ê¾÷Àº °Ô³ð ±â¼úÀÇ Áøº¸¿¡ ÀÇÇØ ÃËÁøµÇ´Â ¸ÂÃãÇü ÀÇ·á ¿¬±¸ÀÇ ±Þ¼ºÀå ºÐ¾ß¸¦ ÀÌ¿ëÇÏ´Â ÀÔÀå¿¡ ÀÖ½À´Ï´Ù. Àΰ£ÀÇ À¯ÀüÀû ´Ù¾ç¼ºÀ» ¹Ý¿µÇÑ ·¡Æ® ¸ðµ¨À» ÀÛ¼ºÇÔÀ¸·Î½á ¿¬±¸ÀÚ´Â °³º° ȯÀÚ¿¡ ¸Â´Â Ä¡·á¸¦ ÇÒ ¼ö ÀÖ°Ô µÇ¾î À¯ÀüÀû º¯À̸¦ Æ÷ÂøÇÒ ¼ö ÀÖ´Â ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °¡¿îµ¥ Çаè¿Í »ý»êÀÚ ¸ðµÎ¿¡°Ô À¯¸®ÇÑ ±âȸ°¡ µË´Ï´Ù. °Ô´Ù°¡ ÀÌ ½ÃÀåÀº Áٱ⼼Æ÷ Ä¡·á³ª Á¶Á÷°øÇÐ µîÀÇ ºÐ¾ß¿¡¼­ ÁãÀÇ Á¶Á÷ Àç»ý ´É·ÂÀ» Ȱ¿ëÇÑ Àç»ý ÀÇ·á ºÐ¾ßÀÇ È®´ë·ÎºÎÅ͵µ ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. Àç»ý ÀÇ·á ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó ·¡Æ® ¸ðµ¨ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ½ÃÀå È®´ë¿Í ´Ù¾çÈ­°¡ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­°¡ ´äº¯ÇÏ´Â ÁÖ¿ä Áú¹®

  • ·¡Æ® ¸ðµ¨ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • ·¡Æ® ¸ðµ¨ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ´Â ¾÷°è´Â?
  • ±â¼úÀÇ Áøº¸´Â ¾î¶»°Ô ·¡Æ® ¸ðµ¨ ½ÃÀå °æÀï ±¸µµ¸¦ ¹Ù²Ù°í Àִ°¡?
  • ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
  • ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú Àå·¡ Àü¸ÁÀº?

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ÁÖ¿ä µ¿Çâ
  • À¯ÇüÀÇ ¶óÀÌÇÁ»çÀÌŬ ºÐ¼®
  • ·¡Æ® ¸ðµ¨ ½ÃÀå : ¹ë·ùüÀÎ
    • ¿øÀç·á °ø±Þ¾÷ü ¸ñ·Ï
    • Á¦Á¶¾÷ü À϶÷
    • ¸®¼¿·¯ À϶÷
    • ¿ëµµ À϶÷
    • ¼öÀͼº ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÁöÁ¤ÇÐÀû ±äÀå: ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
  • °Å½Ã °æÁ¦Àû ¿äÀÎ
    • ¼¼°è ¼½Åͺ° Àü¸Á
    • ¼¼°è GDP ¼ºÀå·ü Àü¸Á
    • ¼¼°è »óÀ§ ½ÃÀå °³¿ä
  • ¿¹Ãø ¿äÀÎ- °ü·Ã¼º°ú ¿µÇâ
  • ±ÔÁ¦¿Í ±â¼úÀÇ »óȲ

Á¦3Àå ¼¼°è ·§Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: ½ÇÀû(2018³â-2022³â)°ú ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
    • ½ÃÀå¼ö·®(À¯´Ö) ¿¹Ãø
    • ½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
    • Àý´ëÀû ÀÌÀÍÀÇ ±âȸ
  • ½ÃÀå ±Ô¸ð(¸¸¹Ì ´Þ·¯) ºÐ¼®°ú ¿¹Ãø
    • °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®(2013³â-2016³â)
    • ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø(2018³â-2026³â)
  • ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: À¯Çü
    • ¼Ò°³/ ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¾ç(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ÇöÀç ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
      • ³ì¾Æ¿ô
      • ÀÌ°è ±³¹è
      • ±Ù±³°è
      • ÇÏÀ̺긮µå
      • ¸é¿ª °áÇÌ
      • Á¶°ÇºÎ
  • ½ÃÀå ¸Å·Âµµ ºÐ¼® : À¯Çü
  • ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á : ±â¼ú
    • ¼Ò°³/ ÁÖ¿ä Á¶»ç °á°ú
    • 2018³âºÎÅÍ 2022³â±îÁöÀÇ ±â¼úº° °ú°Å ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ºÐ¼®
    • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
      • ÇÙÀüÀÌÈ¿¼Ò
      • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
      • ¹è¾Æ Áٱ⠼¼Æ÷
      • ±âŸ
  • ½ÃÀå ¸Å·Â ºÐ¼® : ±â¼ú
  • ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á : ÀÀ¿ë
    • ¼Ò°³/ ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
      • Á¾¾çÇÐ
      • ½Å°æ³»°ú
      • ¸é¿ªÇÐ
      • µ¶¹°ÇÐ
      • ±âŸ
  • ½ÃÀå ¸Å·Â ºÐ¼® : ÀÀ¿ë
  • ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á : ÃÖÁ¾ »ç¿ëÀÚ
    • ¼Ò°³/ ÁÖ¿ä Á¶»ç °á°ú
    • °ú°Å ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
      • CRO
      • Çмú¿¬±¸±â°ü
      • Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚ

Á¦4Àå ¼¼°è ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: Áö¿ª

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • Áö¿ªº° °ú°Å ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í Áö¿ªº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ºÏ¹Ì
    • À¯·´
    • µ¿¾Æ½Ã¾Æ
    • ³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼® :Áö¿ª

Á¦5Àå ºÏ¹ÌÀÇ ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: ½ÇÀû(2018³â-2022³â)°ú ¿¹Ãø(2023³â-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ±¹°¡º°
    • À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
  • ±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ³ì¾Æ¿ô
    • ÀÌ°è ±³¹è
    • ±Ù±³°è
    • ÇÏÀ̺긮µå
    • ¸é¿ª °áÇÌ
    • Á¶°ÇºÎ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ÇÙÀüÀÌÈ¿¼Ò
    • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
    • ¹è¾Æ Áٱ⠼¼Æ÷
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Á¾¾çÇÐ
    • ½Å°æ³»°ú
    • ¸é¿ªÇÐ
    • µ¶¹°ÇÐ
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • CRO
    • Çмú¿¬±¸±â°ü
    • Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦6Àå À¯·´ÀÇ ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: ½ÇÀû(2018³â-2022³â)°ú ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ±¹°¡º°
    • À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
  • ±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ÅÍŰ
    • ±âŸ À¯·´
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ³ì¾Æ¿ô
    • ÀÌ°è ±³¹è
    • ±Ù±³°è
    • ÇÏÀ̺긮µå
    • ¸é¿ª °áÇÌ
    • Á¶°ÇºÎ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ÇÙÀüÀÌÈ¿¼Ò
    • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
    • ¹è¾Æ Áٱ⠼¼Æ÷
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Á¾¾çÇÐ
    • ½Å°æ³»°ú
    • ¸é¿ªÇÐ
    • µ¶¹°ÇÐ
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • CRO
    • Çмú¿¬±¸±â°ü
    • Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦7Àå µ¿¾Æ½Ã¾ÆÀÇ ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: ½ÇÀû(2018³â-2022³â)°ú ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ±¹°¡º°
    • À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
  • ±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Áß±¹
    • ÀϺ»
    • Çѱ¹
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ³ì¾Æ¿ô
    • ÀÌ°è ±³¹è
    • ±Ù±³°è
    • ÇÏÀ̺긮µå
    • ¸é¿ª °áÇÌ
    • Á¶°ÇºÎ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ÇÙÀüÀÌÈ¿¼Ò
    • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
    • ¹è¾Æ Áٱ⠼¼Æ÷
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Á¾¾çÇÐ
    • ½Å°æ³»°ú
    • ¸é¿ªÇÐ
    • µ¶¹°ÇÐ
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • CRO
    • Çмú¿¬±¸±â°ü
    • Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦8Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: ½ÇÀû(2018³â-2022³â)°ú ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ±¹°¡º°
    • À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
  • ±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Àεµ
    • µ¿³²¾Æ½Ã¾Æ
    • ´ºÁú·£µå
    • ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ±âŸ Áö¿ª
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ³ì¾Æ¿ô
    • ÀÌ°è ±³¹è
    • ±Ù±³°è
    • ÇÏÀ̺긮µå
    • ¸é¿ª °áÇÌ
    • Á¶°ÇºÎ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ÇÙÀüÀÌÈ¿¼Ò
    • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
    • ¹è¾Æ Áٱ⠼¼Æ÷
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Á¾¾çÇÐ
    • ½Å°æ³»°ú
    • ¸é¿ªÇÐ
    • µ¶¹°ÇÐ
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • CRO
    • Çмú¿¬±¸±â°ü
    • Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦9Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: ½ÇÀû(2018³â-2022³â)°ú ¿¹Ãø(2023³â-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ±¹°¡º°
    • À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
  • ±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ³ì¾Æ¿ô
    • ÀÌ°è ±³¹è
    • ±Ù±³°è
    • ÇÏÀ̺긮µå
    • ¸é¿ª °áÇÌ
    • Á¶°ÇºÎ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ÇÙÀüÀÌÈ¿¼Ò
    • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
    • ¹è¾Æ Áٱ⠼¼Æ÷
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Á¾¾çÇÐ
    • ½Å°æ³»°ú
    • ¸é¿ªÇÐ
    • µ¶¹°ÇÐ
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • CRO
    • Çмú¿¬±¸±â°ü
    • Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ·¡Æ® ¸ðµ¨ ½ÃÀå Àü¸Á: ½ÇÀû(2018³â-2022³â)°ú ¿¹Ãø(2023-2030³â)

  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • °¡°Ý ºÐ¼®
  • °ú°Å ½ÃÀå ±Ô¸ð¿Í ½ÃÀ庰 ¼ö·®(´ÜÀ§) ºÐ¼®(2018³â-2022³â)
    • ±¹°¡º°
    • À¯Çüº°
    • ¿ëµµº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
  • ±¹°¡º° ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • GCC
    • ÀÌÁýÆ®
    • ³²¾ÆÇÁ¸®Ä«
    • ºÏ¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í À¯Çüº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ³ì¾Æ¿ô
    • ÀÌ°è ±³¹è
    • ±Ù±³°è
    • ÇÏÀ̺긮µå
    • ¸é¿ª °áÇÌ
    • Á¶°ÇºÎ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ±â¼úº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • ÇÙÀüÀÌÈ¿¼Ò
    • ¸¶ÀÌÅ©·Î ÀÎÁ§¼Ç
    • ¹è¾Æ Áٱ⠼¼Æ÷
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ¿ëµµº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • Á¾¾çÇÐ
    • ½Å°æ³»°ú
    • ¸é¿ªÇÐ
    • µ¶¹°ÇÐ
    • ±âŸ
  • ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÃÖÁ¾ »ç¿ëÀÚº° ¼ö·®(´ÜÀ§) ¿¹Ãø(2023³â-2030³â)
    • CRO
    • Çмú¿¬±¸±â°ü
    • Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â
  • ½ÃÀå ±¸Á¶
    • ½ÃÀ庰 °æÀïµµÀÇ ¸ÅÇÎ
    • °æÀï ´ë½Ãº¸µå
    • °Ñº¸±â Á¦Ç° ¿ë·®
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
    • Charles River Laboratories
    • Envigo
    • genOway
    • Laboratory Corporation of America Holdings(LabCorp)
    • Janvier Labs
    • Taconic Biosciences, Inc.
    • TransViragen, Inc.
    • Biomere
    • Cyagen Biosciences

Á¦12Àå ºÎ·Ï

  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦
  • µÎÀÚ¾î ¹× ¾à¾î
BJH 24.05.21

Persistence Market Research has recently published an in-depth analysis of the global Rat Model market, offering a comprehensive overview of key market dynamics, growth drivers, challenges, and emerging trends. This report provides valuable insights into the structure of the Rat Model market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2023 to 2030.

The worldwide Rat Model market is projected to grow at a compound annual growth rate (CAGR) of 6.8%, reaching a valuation of US$2.1 billion by 2030, up from US$1.3 billion in 2023.

Key Insights:

  • Rat Model Market Size (2023E): US$1.3 Bn
  • Projected Market Value (2030F): US$2.1 Bn
  • Global Market Growth Rate (CAGR 2023 to 2030): 6.8%
  • Historical Market Growth Rate (CAGR 2018 to 2022): 7.5%

Rat Model Market- Report Scope:

Rat models, also known as laboratory rats, are integral to scientific inquiry across a spectrum of disciplines including physiology, genetics, behavior, and disease research due to their biological similarities to humans. Leveraging their short reproductive cycles and ease of handling, these models are pivotal in drug development, toxicological analyses, and unraveling complex biological mechanisms. The burgeoning demand for preclinical investigations in pharmaceutical development, propelled by the rise in chronic diseases and advancements in genetic engineering, is fueling substantial growth in the rat model industry. Their ability to mimic diverse human conditions enhances their research utility, driving the overall expansion of the rat model market.

Market Growth Drivers:

Advancements in genetic engineering, notably CRISPR-Cas9 technology, have revolutionized the rat model market by enabling precise genome editing, enhancing the relevance of preclinical investigations. This innovation allows for targeted mutations and gene knockouts, expanding the range of diseases that can be studied using rat models, including cancer and neurological disorders. Concurrently, the escalating prevalence of chronic diseases worldwide, such as diabetes and cardiovascular ailments, fuels the demand for reliable animal models like rats to explore underlying molecular pathways. Leveraging their physiological and genetic resemblance to humans, rat models are indispensable in drug development processes, driving market growth.

Market Restraints:

Translating findings from rat studies to human clinical outcomes poses a notable challenge for the rat model industry, given inherent physiological differences between rats and humans. This limitation hampers the translational relevance of preclinical research, complicating predictions of therapeutic safety and efficacy in humans based solely on rat data. Additionally, ethical and regulatory concerns surrounding animal research, particularly regarding rats, present significant hurdles. Balancing scientific advancements with ethical considerations amidst stricter legal frameworks and growing public concerns adds complexity to navigating the rat model market.

Market Opportunities:

The rat model industry stands to capitalize on the burgeoning field of personalized medicine research, facilitated by advancements in genomic technologies. By creating rat models reflecting human genetic diversity, researchers can tailor treatments to individual patients, driving demand for models capable of capturing genetic variations. This presents a lucrative opportunity for both academia and producers amid the growing interest in personalized medicine. Furthermore, the market can benefit from the expanding field of regenerative medicine, leveraging rats' capacity for tissue regeneration in areas such as stem cell treatments and tissue engineering. As research in regenerative medicine progresses, the demand for rat models is expected to rise, fostering market expansion and diversification.

Key Questions Answered in the Report:

  • What are the key factors driving the growth of the Rat Model Market?
  • Which industry verticals are driving the demand for Rat Model?
  • How are technological advancements reshaping the competitive landscape of the Rat Model Market?
  • Who are the leading players in the global Rat Model Market?
  • What are the emerging trends and future prospects in the global Rat Model Market?

Competitive Intelligence and Business Strategy:

In the competitive rat model market, major players like Charles River Laboratories, Envigo, TransViragen, Biomere, and Cyagen Biosciences lead through extensive R&D and strategic partnerships, ensuring a diverse range of rat models for various research areas. Collaborations with academic institutions bolster their research capabilities, while emerging enterprises specializing in customized or disease-specific rat models contribute to the landscape with cutting-edge technologies. Contract research organizations (CROs) offering comprehensive preclinical services further intensify competition. This dynamic environment fosters continuous innovation, driving the development of new models, breeding methods, and supply chain solutions. Companies differentiate themselves through technological advancements, collaborations, and customer-centric approaches to adapt to evolving research demands.

Key Companies Profiled:

  • Charles River Laboratories
  • Envigo
  • genOway
  • Laboratory Corporation of America Holdings (LabCorp)
  • Janvier Labs
  • Taconic Biosciences, Inc.
  • TransViragen, Inc.
  • Biomere
  • Cyagen Biosciences

Rat Model Market Segmentation:

By Type:

  • Knockout
  • Outbred
  • Inbred
  • Hybrid
  • Immunodeficient
  • Conditioned

By Technology:

  • Nuclear Transferase
  • Microinjection
  • Embryonic Stem Cell
  • Others

By Application:

  • Oncology
  • Neurology
  • Immunology
  • Toxicology
  • Other

By End User:

  • CROs
  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Rat Model Market Snapshot, 2023 and 2030
  • 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Type Lifecycle Analysis
  • 2.4. Rat Model Market: Value Chain
    • 2.4.1. List of Raw Material Supplier
    • 2.4.2. List of Manufacturers
    • 2.4.3. List of Distributors
    • 2.4.4. List of Applications
    • 2.4.5. Profitability Analysis
  • 2.5. Porter Five Force's Analysis
  • 2.6. Geopolitical Tensions: Market Impact
  • 2.7. Macro-Economic Factors
    • 2.7.1. Global Sectorial Outlook
    • 2.7.2. Global GDP Growth Outlook
    • 2.7.3. Global Parent Market Overview
  • 2.8. Forecast Factors - Relevance and Impact
  • 2.9. Regulatory and Technology Landscape

3. Global Rat Model Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 3.1. Key Highlights
    • 3.1.1. Market Volume (Units) Projections
    • 3.1.2. Market Size and Y-o-Y Growth
    • 3.1.3. Absolute $ Opportunity
  • 3.2. Market Size (US$ Mn) Analysis and Forecast
    • 3.2.1. Historical Market Size Analysis, 2013-2016
    • 3.2.2. Current Market Size Forecast, 2018-2026
  • 3.3. Global Rat Model Market Outlook: Type
    • 3.3.1. Introduction / Key Findings
    • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Type, 2018 - 2022
    • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Type, 2023 - 2030
      • 3.3.3.1. Knockout
      • 3.3.3.2. Outbred
      • 3.3.3.3. Inbred
      • 3.3.3.4. Hybrid
      • 3.3.3.5. Immunodeficient
      • 3.3.3.6. Conditioned
  • 3.4. Market Attractiveness Analysis: Type
  • 3.5. Global Rat Model Market Outlook: Technology
    • 3.5.1. Introduction / Key Findings
    • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Technology, 2018 - 2022
    • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
      • 3.5.3.1. Nuclear Transferase
      • 3.5.3.2. Microinjection
      • 3.5.3.3. Embryonic Stem Cell
      • 3.5.3.4. Others
  • 3.6. Market Attractiveness Analysis: Technology
  • 3.7. Global Rat Model Market Outlook: Application
    • 3.7.1. Introduction / Key Findings
    • 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Application, 2018 - 2022
    • 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
      • 3.7.3.1. Oncology
      • 3.7.3.2. Neurology
      • 3.7.3.3. Immunology
      • 3.7.3.4. Toxicology
      • 3.7.3.5. Other
  • 3.8. Market Attractiveness Analysis: Application
  • 3.9. Global Rat Model Market Outlook: End User
    • 3.9.1. Introduction / Key Findings
    • 3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End User, 2018 - 2022
    • 3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
      • 3.9.3.1. CROs
      • 3.9.3.2. Academic and Research Institutes
      • 3.9.3.3. Pharmaceutical & Biotechnology Companies
  • 3.10. Market Attractiveness Analysis: End User

4. Global Rat Model Market Outlook: Region

  • 4.1. Key Highlights
  • 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
  • 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. East Asia
    • 4.3.4. South Asia and Oceania
    • 4.3.5. Latin America
    • 4.3.6. Middle East & Africa (MEA)
  • 4.4. Market Attractiveness Analysis: Region

5. North America Rat Model Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 5.1. Key Highlights
  • 5.2. Pricing Analysis
  • 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 5.3.1. By Country
    • 5.3.2. By Type
    • 5.3.3. By Technology
    • 5.3.4. By Application
    • 5.3.5. By End User
  • 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 5.4.1. U.S.
    • 5.4.2. Canada
  • 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Type, 2023 - 2030
    • 5.5.1. Knockout
    • 5.5.2. Outbred
    • 5.5.3. Inbred
    • 5.5.4. Hybrid
    • 5.5.5. Immunodeficient
    • 5.5.6. Conditioned
  • 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 5.6.1. Nuclear Transferase
    • 5.6.2. Microinjection
    • 5.6.3. Embryonic Stem Cell
    • 5.6.4. Others
  • 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 5.7.1. Oncology
    • 5.7.2. Neurology
    • 5.7.3. Immunology
    • 5.7.4. Toxicology
    • 5.7.5. Other
  • 5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 5.8.1. CROs
    • 5.8.2. Academic and Research Institutes
    • 5.8.3. Pharmaceutical & Biotechnology Companies
  • 5.9. Market Attractiveness Analysis

6. Europe Rat Model Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 6.3.1. By Country
    • 6.3.2. By Type
    • 6.3.3. By Technology
    • 6.3.4. By Application
    • 6.3.5. By End User
  • 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 6.4.1. Germany
    • 6.4.2. France
    • 6.4.3. U.K.
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. T rkiye
    • 6.4.8. Rest of Europe
  • 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Type, 2023 - 2030
    • 6.5.1. Knockout
    • 6.5.2. Outbred
    • 6.5.3. Inbred
    • 6.5.4. Hybrid
    • 6.5.5. Immunodeficient
    • 6.5.6. Conditioned
  • 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 6.6.1. Nuclear Transferase
    • 6.6.2. Microinjection
    • 6.6.3. Embryonic Stem Cell
    • 6.6.4. Others
  • 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 6.7.1. Oncology
    • 6.7.2. Neurology
    • 6.7.3. Immunology
    • 6.7.4. Toxicology
    • 6.7.5. Other
  • 6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 6.8.1. CROs
    • 6.8.2. Academic and Research Institutes
    • 6.8.3. Pharmaceutical & Biotechnology Companies
  • 6.9. Market Attractiveness Analysis

7. East Asia Rat Model Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 7.3.1. By Country
    • 7.3.2. By Type
    • 7.3.3. By Technology
    • 7.3.4. By Application
    • 7.3.5. By End User
  • 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. South Korea
  • 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Type, 2023 - 2030
    • 7.5.1. Knockout
    • 7.5.2. Outbred
    • 7.5.3. Inbred
    • 7.5.4. Hybrid
    • 7.5.5. Immunodeficient
    • 7.5.6. Conditioned
  • 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 7.6.1. Nuclear Transferase
    • 7.6.2. Microinjection
    • 7.6.3. Embryonic Stem Cell
    • 7.6.4. Others
  • 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 7.7.1. Oncology
    • 7.7.2. Neurology
    • 7.7.3. Immunology
    • 7.7.4. Toxicology
    • 7.7.5. Other
  • 7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 7.8.1. CROs
    • 7.8.2. Academic and Research Institutes
    • 7.8.3. Pharmaceutical & Biotechnology Companies
  • 7.9. Market Attractiveness Analysis

8. South Asia & Oceania Rat Model Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 8.3.1. By Country
    • 8.3.2. By Type
    • 8.3.3. By Technology
    • 8.3.4. By Application
    • 8.3.5. By End User
  • 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 8.4.1. India
    • 8.4.2. Southeast Asia
    • 8.4.3. ANZ
    • 8.4.4. Rest of South Asia & Oceania
  • 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Type, 2023 - 2030
    • 8.5.1. Knockout
    • 8.5.2. Outbred
    • 8.5.3. Inbred
    • 8.5.4. Hybrid
    • 8.5.5. Immunodeficient
    • 8.5.6. Conditioned
  • 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 8.6.1. Nuclear Transferase
    • 8.6.2. Microinjection
    • 8.6.3. Embryonic Stem Cell
    • 8.6.4. Others
  • 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 8.7.1. Oncology
    • 8.7.2. Neurology
    • 8.7.3. Immunology
    • 8.7.4. Toxicology
    • 8.7.5. Other
  • 8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 8.8.1. CROs
    • 8.8.2. Academic and Research Institutes
    • 8.8.3. Pharmaceutical & Biotechnology Companies
  • 8.9. Market Attractiveness Analysis

9. Latin America Rat Model Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 9.3.1. By Country
    • 9.3.2. By Type
    • 9.3.3. By Technology
    • 9.3.4. By Application
    • 9.3.5. By End User
  • 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Type, 2023 - 2030
    • 9.5.1. Knockout
    • 9.5.2. Outbred
    • 9.5.3. Inbred
    • 9.5.4. Hybrid
    • 9.5.5. Immunodeficient
    • 9.5.6. Conditioned
  • 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 9.6.1. Nuclear Transferase
    • 9.6.2. Microinjection
    • 9.6.3. Embryonic Stem Cell
    • 9.6.4. Others
  • 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 9.7.1. Oncology
    • 9.7.2. Neurology
    • 9.7.3. Immunology
    • 9.7.4. Toxicology
    • 9.7.5. Other
  • 9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 9.8.1. CROs
    • 9.8.2. Academic and Research Institutes
    • 9.8.3. Pharmaceutical & Biotechnology Companies
  • 9.9. Market Attractiveness Analysis

10. Middle East & Africa Rat Model Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 10.3.1. By Country
    • 10.3.2. By Type
    • 10.3.3. By Technology
    • 10.3.4. By Application
    • 10.3.5. By End User
  • 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 10.4.1. GCC
    • 10.4.2. Egypt
    • 10.4.3. South Africa
    • 10.4.4. Northern Africa
    • 10.4.5. Rest of Middle East & Africa
  • 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Type, 2023 - 2030
    • 10.5.1. Knockout
    • 10.5.2. Outbred
    • 10.5.3. Inbred
    • 10.5.4. Hybrid
    • 10.5.5. Immunodeficient
    • 10.5.6. Conditioned
  • 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Technology, 2023 - 2030
    • 10.6.1. Nuclear Transferase
    • 10.6.2. Microinjection
    • 10.6.3. Embryonic Stem Cell
    • 10.6.4. Others
  • 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
    • 10.7.1. Oncology
    • 10.7.2. Neurology
    • 10.7.3. Immunology
    • 10.7.4. Toxicology
    • 10.7.5. Other
  • 10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 10.8.1. CROs
    • 10.8.2. Academic and Research Institutes
    • 10.8.3. Pharmaceutical & Biotechnology Companies
  • 10.9. Market Attractiveness Analysis

11. Competition Landscape

  • 11.1. Market Share Analysis, 2022
  • 11.2. Market Structure
    • 11.2.1. Competition Intensity Mapping By Market
    • 11.2.2. Competition Dashboard
    • 11.2.3. Apparent Product Capacity
  • 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 11.3.1. Charles River Laboratories
      • 11.3.1.1. Overview
      • 11.3.1.2. Segments and Product
      • 11.3.1.3. Key Financials
      • 11.3.1.4. Market Developments
      • 11.3.1.5. Market Strategy
    • 11.3.2. Envigo
      • 11.3.2.1. Overview
      • 11.3.2.2. Segments and Product
      • 11.3.2.3. Key Financials
      • 11.3.2.4. Market Developments
      • 11.3.2.5. Market Strategy
    • 11.3.3. genOway
      • 11.3.3.1. Overview
      • 11.3.3.2. Segments and Product
      • 11.3.3.3. Key Financials
      • 11.3.3.4. Market Developments
      • 11.3.3.5. Market Strategy
    • 11.3.4. Laboratory Corporation of America Holdings (LabCorp)
      • 11.3.4.1. Overview
      • 11.3.4.2. Segments and Product
      • 11.3.4.3. Key Financials
      • 11.3.4.4. Market Developments
      • 11.3.4.5. Market Strategy
    • 11.3.5. Janvier Labs
      • 11.3.5.1. Overview
      • 11.3.5.2. Segments and Product
      • 11.3.5.3. Key Financials
      • 11.3.5.4. Market Developments
      • 11.3.5.5. Market Strategy
    • 11.3.6. Taconic Biosciences, Inc.
      • 11.3.6.1. Overview
      • 11.3.6.2. Segments and Product
      • 11.3.6.3. Key Financials
      • 11.3.6.4. Market Developments
      • 11.3.6.5. Market Strategy
    • 11.3.7. TransViragen, Inc.
      • 11.3.7.1. Overview
      • 11.3.7.2. Segments and Product
      • 11.3.7.3. Key Financials
      • 11.3.7.4. Market Developments
      • 11.3.7.5. Market Strategy
    • 11.3.8. Biomere
      • 11.3.8.1. Overview
      • 11.3.8.2. Segments and Product
      • 11.3.8.3. Key Financials
      • 11.3.8.4. Market Developments
      • 11.3.8.5. Market Strategy
    • 11.3.9. Cyagen Biosciences
      • 11.3.9.1. Overview
      • 11.3.9.2. Segments and Product
      • 11.3.9.3. Key Financials
      • 11.3.9.4. Market Developments
      • 11.3.9.5. Market Strategy

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Research Assumptions
  • 12.3. Acronyms and Abbreviations
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦